Saudi Arabia Diabetes Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The saudi arabia diabetes devices market size is projected to be USD 693.90 million in 2025, USD 722.46 million in 2026, and reach USD 884.52 million by 2031, growing at a CAGR of 4.12% from 2026 to 2031. This report is Segmented Into Device Category (Monitoring Devices and Management Devices), End User (Hospitals & Clinics, Home-Care Settings, and Retail Pharmacies & Diabetes Centers), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce / Online Pharmacies), and Diabetes Type (Type-1 Diabetes, Type-2 Diabetes, and Gestational & Other Specific Types).

Saudi Arabia Diabetes Devices Market Trends and Insights

Growing Prevalence of Obesity & Associated Diabetes

Accelerating obesity rates have enlarged the pool of individuals at risk for type 2 diabetes, directly lifting demand for monitoring and management solutions. Peer-reviewed studies place the national adult obesity prevalence above one-quarter of the population, a level that correlates with sharp increases in new diabetes diagnoses . An inference from recent hospital admissions data is that newly diagnosed patients are presenting with higher baseline HbA1c values, which in turn raises immediate need for more intensive device support. As a consequence, manufacturers of CGM sensors and insulin pens observe faster reorder cycles in urban centers where obesity rates are highest.

Rising Geriatric Population

The share of residents aged 65 years and older is rising faster than the overall population, and this cohort displays an elevated incidence of diabetes complications that necessitate specialized devices. Government statistics show an upward trend in age-related comorbidities, such as neuropathy, pushing hospitals to adopt devices that integrate dose reminders and larger font displays. A clear knock-on effect is that vendors are tailoring marketing messages around ease of use, signaling that ergonomics can be a differentiator in procurement cycles. Concurrently, geriatric specialists are advocating for broader reimbursement of insulin pumps, contending that automated delivery reduces caregiver burden, which may influence future coverage decisions.

Stringent Regulations

SFDA requirements mandate proof of prior clearance in a Global Harmonization Task Force member state, a provision that elongates time-to-market for novel products but also reassures clinicians about product safety. Compliance costs compel foreign suppliers to favor partnerships with established local distributors that already hold quality-management certifications. A visible effect is that small innovators are increasingly opting for technology-licensing deals rather than direct entry, altering the competitive dynamics in favor of firms able to finance regulatory navigation.

Other drivers and restraints analyzed in the detailed report include:

• Integration of Digital Health Solutions
• National Diabetes Screening Program Expansions
• High Import Tariffs on Bluetooth-Enabled Glucometers

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The monitoring sub-segment commands the largest share of the diabetes devices market and accounted for the bulk of revenue in 2025, with self-monitoring blood glucose (SMBG) devices accounting for 61.35% of sales that year. Penetration reflects decades of clinician familiarity, wide insurance coverage for test strips, and lower upfront costs. Recurring strip consumption guarantees predictable cash flow for pharmacies, allowing them to negotiate favorable wholesale prices, which sustains the dominance of SMBG despite emerging alternatives. One interesting detail is that private insurers are beginning to cap strip reimbursements, which may indirectly encourage users to migrate toward CGM solutions that have lower strip dependency.

Management devices accounted for a sizeable share of the diabetes devices market, holding 38.65% in 2025, due to their single-use convenience and lower infection risk. Hospitals favor them for inpatient wards because they simplify stock control, and pharmacists highlight dosage accuracy as a clinical advantage. A corollary is that local compounding of insulin solutions is declining, reflecting a broader supply-chain modernization that reduces medication errors.

Hospitals and clinics accounted for 54.40% of the diabetes devices market share in 2025, driven by centralized specialized care and government funding. In-house diabetes centers rely on structured education programs that standardize device selection, which explains the consistent bulk orders placed with major distributors. Because reimbursement claims often originate within hospital settings, prescribing physicians possess considerable leverage over brand choice, reinforcing incumbent positions.

Home-care settings are on track for a 4.62% CAGR between 2026 and 2031, the fastest pace among end-user categories. Drivers include patient preference for convenience and health-system efforts to manage chronic diseases outside hospital walls. Telemedicine consultations surged during pandemic lockdowns, normalizing remote data exchange and building patient confidence in self-management practices. Evidence that one-quarter of telehealth participants achieved clinically meaningful HbA1c improvements suggests that home-based monitoring can be equally effective, encouraging payers to refine remote-care reimbursement policies.

Complete Report Scope:

• By Device Category
  • Monitoring Devices
    • Self-Monitoring Blood Glucose (SMBG) Devices
      • Glucometers
      • Test Strips
      • Lancets
    • Continuous Glucose Monitoring (CGM) Devices
      • Sensors
      • Durables (Receivers & Transmitters)
  • Management Devices
    • Insulin Delivery Devices
      • Insulin Pump Devices
      • Insulin Disposable Pens
      • Insulin Cartridges in Re-usable Pens
      • Insulin Syringes & Jet Injectors
• By End User
  • Hospitals & Clinics
  • Home-Care Settings
  • Retail Pharmacies & Diabetes Centers
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-commerce / Online Pharmacies
• By Diabetes Type
  • Type-1 Diabetes
  • Type-2 Diabetes
  • Gestational & Other Specific Types

List of Companies Covered in this Report:

• Abbott Laboratories
• Roche
• Medtronic
• Dexcom
• Novo Nordisk
• Sanofi
• Eli Lilly and Company
• Becton Dickinson and Co.
• Ascensia
• Johnson & Johnson
• Arkray
• Ypsomed
• Terumo
• Insulet
• Tandem Diabetes Care
• Senseonics Holdings
• Nipro
• Menarini Diagnostics
• Trividia Health
• Owen Mumford

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support